RA Capital Management 13F holdings, Q4 2019
Holdings as of December 31, 2019 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 34 US equity positions worth $3.3bn in its Q4 2019 13F filing. The largest position was SYNTHORX INC at 20.6% of the reported book, followed by ASND and RA PHARMACEUTICALS INC. Against the Q3 2019 filing, it opened 9 new positions, added to 7 and reduced 2 among the top 34 holdings.
What did RA Capital Management own in Q4 2019? Top 34 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2019 |
|---|---|---|---|---|---|---|---|
| 1 | SYNTHORX INC | 20.6% | $679.7m | 9,724,598 | 0% | held | |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 17.7% | $582.3m | 4,185,342 | 1% | added |
| 3 | RA PHARMACEUTICALS INC | 6.9% | $228.0m | 4,858,260 | 0% | held | |
| 4 | ARVN ARVINAS INC | Healthcare | 4.6% | $150.9m | 3,672,872 | 121% | added |
| 5 | CHEMOCENTRYX INC | 3.8% | $126.5m | 3,199,389 | – | new | |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.8% | $124.5m | 5,422,312 | 58% | added |
| 7 | EIDOS THERAPEUTICS INC | 3.8% | $124.1m | 2,162,671 | 0% | held | |
| 8 | ZOGENIX INC | 3.6% | $117.9m | 2,260,751 | 0% | held | |
| 9 | PHAT PHATHOM PHARMACEUTICALS INC | 3.4% | $113.6m | 3,646,808 | – | new | |
| 10 | TGTX TG THERAPEUTICS INC | Healthcare | 3.3% | $109.7m | 9,880,323 | 44% | added |
| 11 | SATSUMA PHARMACEUTICALS INC | 2.8% | $92.1m | 4,681,858 | 0% | held | |
| 12 | ORCHARD THERAPEUTICS PLC | 2.7% | $87.9m | 6,389,901 | 22% | added | |
| 13 | 89BIO INC | 2.5% | $83.1m | 3,161,214 | – | new | |
| 14 | FORTY SEVEN INC | 2.3% | $76.1m | 1,933,250 | – | new | |
| 15 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.9% | $62.3m | 7,775,207 | 0% | held |
| 16 | RETROPHIN INC | 1.8% | $60.4m | 4,252,453 | 7% | added | |
| 17 | AUDENTES THERAPEUTICS INC | 1.6% | $54.0m | 902,383 | – | new | |
| 18 | PREVAIL THERAPEUTICS INC | 1.6% | $53.2m | 3,363,605 | 0% | held | |
| 19 | CRINETICS PHARMACEUTICALS INC | 1.4% | $47.0m | 1,875,209 | 0% | held | |
| 20 | ARDX ARDELYX INC | Healthcare | 1.2% | $40.2m | 5,358,863 | – | new |
| 21 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.2% | $38.0m | 367,816 | -45% | reduced |
| 22 | IGM BIOSCIENCES INC | 1.1% | $37.5m | 982,723 | 111% | added | |
| 23 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.0% | $31.7m | 1,119,963 | 0% | held |
| 24 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.9% | $29.7m | 761,666 | – | new |
| 25 | MNTA MOMENTA PHARMACEUTICALS INC | 0.9% | $28.5m | 1,445,801 | – | new | |
| 26 | SLDB SOLID BIOSCIENCES INC | 0.6% | $20.3m | 4,571,164 | 0% | held | |
| 27 | SCPHARMACEUTICALS INC | 0.6% | $18.4m | 3,247,005 | 0% | held | |
| 28 | ALEC ALECTOR INC | Healthcare | 0.5% | $17.2m | 1,000,000 | 0% | held |
| 29 | KALA PHARMACEUTICALS INC | 0.5% | $16.7m | 4,537,478 | 0% | held | |
| 30 | GALERA THERAPEUTICS INC | 0.4% | $13.9m | 1,054,178 | – | new | |
| 31 | DVAX DYNAVAX TECHNOLOGIES CORP | 0.4% | $13.5m | 2,365,912 | 0% | held | |
| 32 | PORTOLA PHARMACEUTICALS INC | 0.3% | $10.3m | 429,399 | 0% | held | |
| 33 | ESSA PHARMA INC | 0.2% | $5.5m | 1,000,000 | 0% | held | |
| 34 | XFOR X4 PHARMACEUTICALS INC | 0.1% | $2.9m | 270,292 | -43% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.